Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The first step? Getting lawmakers to start addressing this is BIG in my mind. While this bill will fall short - think of a more comprehensive bill or plan to tax Everything from Cuba! Feels like something could be brewing in the next year or two...
http://www.miamiherald.com/news/nation-world/world/americas/cuba/article153788524.html
Great DD bro! Well done. $TRKG
Bought more this morning. Want more under 3!
News today...
Immune Therapeutics to Present at the 7th Annual LD Micro Invitational
Jun 05, 2017
OTC Disclosure & News Service
-
LOS ANGELES, CA / ACCESSWIRE / June 5, 2017 / Immune Therapeutics, Inc. (OTCQB: IMUN), a specialty pharmaceutical company focused on developing and commercializing our novel patented, affordable, non-toxic therapy for the management of cancer, HIV, autoimmune diseases, and other inflammatory conditions, today announced that it will be presenting at the 7th annual LD Micro Invitational on Wednesday, June 7 at 9:00 AM PST / 12:00 PM EST. Chief Executive Officer, Noreen Griffin, will be giving the presentation and meeting with investors.
Immune Therapeutics recently announced that it has received NAFDAC (National Agency for Food and Drug Administration and Control) approval to market and distribute LodonalTM, the Company's breakthrough treatment for HIV/AIDS in Nigeria. The Company and its strategic partners plan to immediately initiate sales activities of this first-to-market opportunity.
"With Immune Therapeutics' recently announced debt restructuring, the company is well positioned to move forward with its business plan, which calls for a significant ramp-up in revenues and achievement of profitability by the end of the fourth quarter," stated Ms. Griffin. "In addition to Nigeria, the company expects to obtain regulatory approvals in Kenya, Senegal, and Cote d'Ivoire by the fourth quarter of 2017 or early in 2018. We are very proud of the many achievements this company has made over the past several years and look forward to updating our shareholders on our commercialization strategy followed by the announcement of initial contracts."
"This year, not only do we have a record number of companies making their LD Micro debuts, but a record number of companies presenting for the first time in their company's history," stated Chris Lahiji, President of LD Micro. "LD has established itself as the one venue that brings the most influential players from all segments of the market under one roof."
The conference will be held at the Luxe Sunset Bel Air Hotel and will feature 180 companies in the small / micro-cap space.
View Immune Therapeutics' profile here: https://www.ldmicro.com/profile/IMUN
Profiles powered by LD Micro - News Compliments of ACCESSWIRE.
About Immune Therapeutics, Inc.
Immune Therapeutics, Inc. (OTCQB: IMUN) is a clinical-stage biopharmaceutical company developing its proprietary version of lower-dose naltrexone, Lodonal™, as a standalone and conjunctive therapy in patients with a wide variety of conditions including HIV/AIDS, autoimmune diseases, cancer, neurodegenerative conditions and other inflammatory conditions. Lodonal™ is a novel compound with a unique mechanism of action and has clinical data on over 2,000 patients in several clinical studies. The drug has a favorable safety profile, is well tolerated by patients and has demonstrated efficacy in at least one clinically meaningful endpoint.
About LD Micro
LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event).
In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and microcap universe.
For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.
Forward-Looking Statements
This release may contain forward-looking statements. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to, the possibility that some or all of the matters and transactions considered by the Company may not proceed as contemplated, and by all other matters specified in the Company's filings with the Securities and Exchange Commission. These statements are made based upon current expectations that are subject to risk and uncertainty. The Company does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information. Assumptions and other information that could cause results to differ from those set forth in the forward-looking information can be found in the Company's filings with the Securities and Exchange Commission (www.sec.gov), including its recent periodic reports.
Investor/Media Contact:
Bill Miller
Investor Relations Partners
Phone: 844-565-5665
bmiller@irpartnersinc.com
SOURCE: Immune Therapeutics, Inc.
Copyright © 2017 Accesswire. All Rights Reserved
Well your opinion doesn't mean much here lol. New company with rev generating acquisition backed by fund manager (Pamria), yeah sounds brutal. Plus AS almost maxed and 70mil of OS is restricted. I don't care what you think, but on your first post calling this garbage when it just started is telling. I hope you fill your bid too ;)
Relax or move on. No need to blast here if you're not interested.
Enjoy the ride!
Hi Deet,
To answer your questions - the MAX conversion per the last company filing (1990) said they can convert between 5 to 20 shares of commons. I would assume 20 at this price? But honestly I don't know that they would convert. They have preference for payout over commons, which is how most preferred shares work. But worst case payout to commons (if we see full payout and my math was correct?)...and this was assumed extra conservative was about $115 per share after debt and preferred are paid off.
I 'think' the debt from the claim was written off decades ago when they transitioned to the new company name (Manati Sugar to Manati Industries). It appears the new debt was created on loans from Bangor Punta, a subsidiary of theirs. I think Bangor was strictly in the US and didn't have issues when MNII was confiscated. They used a loan from them to start an airline, which was unsuccessful ultimately along with some other ventures. Now they sit and wait for the claim payment vs going into more debt.
Since 1990 it looks like they had admin debt and accumulated debt from preferred share assumptions. Looks like at the time of about $25k per quarter. So I'm assuming about $3.5mil debt before preferred payment. So not much compared to the original claim. And it sounds like the debt on hand is negotiable since the debt is to Bangor and they already own the preferred shares. So I am assuming worse case in my calculations, but it could be much better.
Have a good one.
Interesting article Deet. While not the cure-all, if more bills are passed similar to this maybe we can compile enough income to pay off the claims. Arguments from both sides, but at least someone is using their head and leveraging the situation of claims to find a happy medium for all. Maybe soon we can get some real progress.
Updated sticky with today's news and will update ibox later. Adding on dips here!
Selling on this news??? Wow, someone must not like money smh lol
Lots of shares getting bought above .03 last two days. VWAP shows this going to move higher...
Very nice! More acquisitions coming I'm sure...
Never mind I found it on the companies website. This looks like an intriguing buy here. I put in for some this morning. Looks like payout could be 4-5x current PPS if sales fetch a nice value for assets.
This is going to be a good one! $TRKG
$PRXIQ interesting one. Liquidating all assets and paying out to all equity holders if approved. They own $230+mil assets if sold to market value (RMS Titanic artifacts, rights, other artifacts, etc...). At current PPS payout could be 4x that if all goes well. OS is a little under 8mil.
No problem. From what I've seen they always have news posted there immediately and follow it up with 8-k next day. I'm assuming that's when most boards see the news if they aren't linked to OTC news or searching for it directly. I would assume the 8-k hits shortly.
Go $IMUN
It was on OTC page for IMUN news. I just check every day because I miss stuff too looking at other sources. It surprised me as well lol.
Just throwing this out there...
Thanks for clarifying that! I forgot all about the DR one. Makes you wonder if they'll shift production eventually if costs are cheaper? And trans to other African countries much be much cheaper from Nigeria? Be interesting to watch...
Where do you see the $218mil figure? I saw $110 in their filings from when they were given the assets from 2010. Can you show me where you saw that different figure? It's a substantial difference...
Very nice! I'm happy to invest here and feel good about what my money is going towards.
All good. I'm with you dwarren - the contracts are already established (imo). I think they are just waiting to make sure everything is in place and first sales are done before they officially PR anything about contracts. A smart company would do that.
In looking back through some of the PRs and news from sites - it's clear that IMUN is already setup and rolling with Fidson Healthcare. I like this:
Hold your shares folks! R/M coming...
Dempsey Mork is on the nvsos page that was recently updated. Check this out: www.reversemergeradvisors.com
This should move up nicely once filings hit. $GNCC
Immune Therapeutics Signs Memorandum of Understanding for Distribution of Lodonal™ in Côte d’Ivoire and acquires COPP for Côte d’Ivoire; Company Plans for Approval of Lodonal in Côte d’Ivoire in 201
May 31, 2017
OTC Disclosure & News Service
-
ORLANDO, Fla., May 31, 2017 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTCQB:IMUN), a specialty pharmaceutical company focused on developing and commercializing our novel patented, affordable, non-toxic therapy for the management of cancer, HIV, autoimmune diseases, and other inflammatory conditions, today announced that it has signed a Memorandum of Understanding (“MOU”) for the distribution of its patented Lodonal™ in Côte d’Ivoire (the Ivory Coast).
The MOU is between Immune Therapeutics, GB Pharma Holdings and Rougier Pharma Afrique SA and sets forth a framework for the future standard terms and conditions for distributing Lodonal in Côte d’Ivoire. With a population of 27 million, Cote d’Ivoire has the fastest growing economy of the African continent and the third-fastest in the world in 2016, and the African Development Bank (AfDB) projects the country’s GDP to grow at approximately 8.3% in 2017. Côte d’Ivoire has experienced an impressive turnaround since 2011, with economic growth averaging about 9% per year. The economic outlook remains strong and is supported by strategies explained in the ‘National Development Plan (NDP) 2016-20’. The NDP prioritizes inclusive and sustainable growth; focusing on structural transformation and improving quality of life for all Ivorians.
The issuance of a Certificate of Pharmaceutical Product (“COPP”) has granted the Company a license to export Lodonal to Côte d’Ivoire, which has been authorized by the Dominican Republic Ministry of Public Health. Now the Company is ready to submit a New Drug Application (“NDA”) to Directorate of Pharmacy and Medicines. The application will include the following information, COPP, Proof of cGMP, Certificate of Analysis, Dossier, Patient Data Sheet, Packaging and all clinical data supporting the request for approval. Included with the clinical data were the results of four phase II clinical trials and one bridging trial clinical trials HIV/AIDS with more than 500 patients, as well as 89 patients for cancer, 250 patients for autoimmune and inflammation diseases.
The Company plans to position Lodonal within the Pharmacie de la Santé Publique (PSP) as an immune booster and adjunct immune therapy for cancer and HIV/AIDS. The PSP is an integral part of universal healthcare provided by the government as part of its public health policy. With a national prevalence rate of HIV estimated at 3.7%, the impact of the HIV/AIDS pandemic is such that it represents the first cause of death for men and the second for women (the first being problems during pregnancy and childbirth).
Immune Therapeutics, GB Pharma and Rougier expect to finalize an exclusive, definitive agreement within the next 60 to 90 days and should be in a position to provide purchase orders and commence distribution immediately upon approval by Directorate of Pharmacy and Medicines.
The Company anticipates distribution and sales of Lodonal in Côte d’Ivoire by the end of 2017. Rougier is leading the approval process in country with the support of IMUN and GB Pharma. Once drug approval is obtained in Côte d’Ivoire, Rougier intends to expand distribution to Benin, Togo, Burkina Faso, Niger and Gabon after facilitating the approvals in these countries as well.
Commenting on the MOU, Noreen Griffin, Chief Executive Officer of Immune Therapeutics, said, “This is our next step in making Lodonal available to millions of people in Africa and hopefully around the world that suffer from HIV. HIV therapy does not fully restore health. For reasons that remain to be elucidated, antiretroviral-treated HIV disease is now associated with a new constellation of problems, generally referred to as “non-AIDS morbidity”. Lodonal has been shown as an immunomodulator to helping offset the toxic side effects of ART therapy, which will improve the quality of life for HIV/AIDS patients throughout the world.”
Dr. Gloria B. Herndon, President and CEO of GB Pharma Holdings, said, “This is yet another successful milestone as we accelerate our strategy of providing Lodonal as the first affordable non-toxic therapies throughout Africa. By forming a relationship with Rougier Pharma we again have a top distributor in the region.”
Rougier Managing Director, Mr. Faustin Kouassi, said, “We are very proud to be part of an initiative that brings innovative and effective immune therapy to those in need in Côte d’Ivoire”
About HIV
HIV stands for the Human Immunodeficiency Virus. Unlike some other viruses, the human body cannot get rid of HIV, so once someone has HIV they have it for life. There is no cure for HIV, but effective treatment can control the virus so that people with HIV can enjoy healthy and productive lives. There are approximately 37 million people living with HIV/AIDS around the world, with 25.5 million of them living in Africa.
About Lodonal
Lodonal is an opiate antagonist shown to act as an immune modulator that works by rebalancing the immune system. Lodonal blocks the opiate receptors temporarily (typically 2-4 hours) leading to rebound increase in endogenous opioids, endorphins and met (5) enkephalin or OGF involved in regulating immune function & cell proliferation.
Lodonal’s approval as a daily oral Immune System Regulator for the management of HIV/AIDS is based on the results of a 90-Day bridging trial and several Phase II multi-center, randomized studies demonstrating that patients treated with Lodonal reported significant improvements when compared with counterparts receiving placebo.
Trials in Nigeria showed that the drug was able to offset the toxic side effects of the HIV therapy, reduce inflammation and opportunistic infections, making Lodonal possibly the first non-toxic adjunct therapy that improves the life of millions of people taking HIV medication.
About Immune Therapeutics, Inc.
Immune Therapeutics, Inc. (OTCQB:IMUN) is a clinical-stage biopharmaceutical company developing its proprietary version of lower-dose naltrexone, Lodonal™, as a standalone and conjunctive therapy in patients with a wide variety of conditions including HIV/AIDS, autoimmune diseases, cancer, neurodegenerative conditions and other inflammatory conditions. Lodonal is a novel compound with a unique mechanism of action and has clinical data on over 2,000 patients in several clinical studies. The drug has a favorable safety profile, is well tolerated by patients and has demonstrated efficacy in at least one clinically meaningful endpoint.
About GB Pharma Holdings
GB Pharma Holdings is a Washington D.C. global pharmaceutical consulting company with expertise in defining policies, facilitating approvals, distribution and cGMP (current Good Manufacturing Practices) and introducing innovative therapies to Africa. It was established in order to be on the forefront of change and is dedicated to bringing cost effective and quality products to Africa. GB Pharma Holdings is able to link new technologies, science and education together to be a cause for good. Its core focus is twofold; facilitate manufacturing of cGMP quality pharmaceuticals and helping existing government agencies develop testing and regulations to purge counterfeit and sub-potent products out of their respective countries.
About Rougier Pharma Afrique SA
Rougier is a pharmaceutical company that is involved in the manufacturing, distribution, marketing and import and export of pharmaceuticals. It also has presence also in Burkina Faso, Togo, Niger and Gabon. With three primary lines, it is one of the oldest and fastest growing pharmaceutical companies in Côte d’Ivoire.
Forward-Looking Statements
This release may contain forward-looking statements. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to, the possibility that some or all of the matters and transactions considered by the Company may not proceed as contemplated, and by all other matters specified in the Company's filings with the Securities and Exchange Commission. These statements are made based upon current expectations that are subject to risk and uncertainty. The Company does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information. Assumptions and other information that could cause results to differ from those set forth in the forward-looking information can be found in the Company's filings with the Securities and Exchange Commission (www.sec.gov), including its recent periodic reports.
Investor/Media Contact:
Bill Miller
Investor Relations Partners
Phone: 844-565-5665
bmiller@irpartnersinc.com
Copyright © 2017 GlobeNewswire. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
News out. Côte d'Ivoire MOU with sales likely by EOY 2017 and def agreement in 60 to 90 days :) SO undervalued now...
Fair enough. I loaded this morning and might add more. Either way, low float with incoming merger looks like.
Thank you. Interesting. Following the OTC page, it links to GTalk website which lists a nvsos # on the bottom right, and that # links to Genco USA Corp in nvsos. So am confused on which one is right? GTalk is owned by massive Japanese company, but your way looks right. Oxford Corp it is! I'm happy either way. Just two different breadcrumb trails.
Hey how did you see Oxford as the new business name? I'm not seeing that...but I'm not totally nvsos savvy. I still see Genco USA Corp as revoked, but can't find the connection.
New company looks like big deal...Oxford Corp. Loaded some..,
It looks like about $7.1mil they owe to note holders and default penalties. So at today's price, it would be about 120mil shares if everything converted. However, that's unreasonable and unlikely. Many of the default notes haven't collected yet...and I assume there is a reason why. They don't want to convert and drive the price to zero with revs so close. I think/hope the company puts some of its revs to paying off these notes for shareholders and note holders. Until then, we'll continue to see a slow trickle of conversions. Revs will fix this rapidly...we just need some contract news with big money attached.
Looking great here! DD is truly top notch. Looking for an explosion soon. Company getting its act together for a reason. SS is top notch. Ready... $TRKG
Amen! We're just starting here. I was fortunate to get in near the low, but have bought all the way back up. This is a long term hold and have put many shares in my kids portfolios. Sales will tell the tale of where this is headed and potential, but I believe we are destined for better things here. $IMUN
Crush that wall and we're off!
And there you go... lol
Looks like good things happening behind scenes. I'm in today! I like these ones... $TRKG
I think Lucid motors is still private. They'll probably IPO vs merge into an OTC ticker. Just keep following company for news.
Just curious why you think this ticker is associated with Lucid motors? I don't see the proof anywhere. Name is close, but no connections I see... tyia
It's about to get crazy up in here lol
Interesting trading today. Massive blocks going through, but none showing on L2 ahead of time at those prices.
Gonna be a good one!
Makes sense for the most part. I think if dilution or sellers came out after the news, we would have seen a push down on larger volume. So far we're floating around between the 50ma and 200ma on light volume. Not a bad thing...was just expecting a double volume kind of day on the 8-k.
I guess I look at this like a blessing. Less eyes on this than I originally thought. Makes buying ops short term. Can't imagine we don't see long term growth. So far from when I jumped on management is delivering! They say profitable by EOY and dilution loans do to. I can wait 2-3 quarters to see this proof.
One thing I did notice is that the word "contracts" was plural. I like that.
Reading back through the Jan 30 letter to shareholders, its all lining up. All of it. Major cash flow by end of Q2, profitable by end of 2017, self-funded by end of 2017, fast track approvals from other African countries, using NAFDAC approval as fast track for MENK approval for cancer, and possible Cytocom spin off. That's a lot. BUT, in all fairness I think investors are shy here. Due to 2014 claims of big revs which didn't happen, and more dilution followed, I can see how people want to see the rev proof first.
But I keep remembering that there are some big backers here and it looks like the time is now. I'm glad I'm in mostly in the low 3s as it makes holding this long term a no-brainer.